DLL3 as a potential diagnostic and therapeutic target in neuroendocrine neoplasms: A narrative review

IF 5.5 2区医学 Q1 HEMATOLOGY

Critical reviews in oncology/hematology Pub Date : 2024-09-24 DOI:10.1016/j.critrevonc.2024.104524

Annarita Peddio , Erica Pietroluongo , Maria Rosaria Lamia , Angelo Luciano , Aldo Caltavituro , Roberto Buonaiuto , Giovanna Pecoraro , Pietro De Placido , Giovannella Palmieri , Roberto Bianco , Mario Giuliano , Alberto Servetto

{"title":"DLL3 as a potential diagnostic and therapeutic target in neuroendocrine neoplasms: A narrative review","authors":"Annarita Peddio , Erica Pietroluongo , Maria Rosaria Lamia , Angelo Luciano , Aldo Caltavituro , Roberto Buonaiuto , Giovanna Pecoraro , Pietro De Placido , Giovannella Palmieri , Roberto Bianco , Mario Giuliano , Alberto Servetto","doi":"10.1016/j.critrevonc.2024.104524","DOIUrl":null,"url":null,"abstract":"<div><div>Neuroendocrine neoplasms (NENs) represent a diagnostic and therapeutic challenge, due to their heterogeneity and limited treatment options. Conventional imaging techniques and therapeutic strategies may become unreliable during follow-up, due to the tendency of these neoplasms to dedifferentiate over time. Therefore, novel diagnostic and therapeutic options are required for the management of NEN patients. Delta-like ligand 3 (DLL3), an inhibitory ligand of Notch receptor, has emerged as a potential target for novel diagnostic and therapeutic strategies in NENs, since overexpression of DLL3 has been associated with tumor progression, poor prognosis and dedifferentiation in several NENs. This narrative review examines the current evidence about DLL3, its structure, function and association with tumorigenesis in NENs. Ongoing studies exploring the role of DLL3 as an emerging diagnostic marker are reviewed. Promising therapeutic options, such as antibody-conjugated drugs, CAR-T cells and radioimmunoconjugates, are also discussed.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"204 ","pages":"Article 104524"},"PeriodicalIF":5.5000,"publicationDate":"2024-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Critical reviews in oncology/hematology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1040842824002671","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Neuroendocrine neoplasms (NENs) represent a diagnostic and therapeutic challenge, due to their heterogeneity and limited treatment options. Conventional imaging techniques and therapeutic strategies may become unreliable during follow-up, due to the tendency of these neoplasms to dedifferentiate over time. Therefore, novel diagnostic and therapeutic options are required for the management of NEN patients. Delta-like ligand 3 (DLL3), an inhibitory ligand of Notch receptor, has emerged as a potential target for novel diagnostic and therapeutic strategies in NENs, since overexpression of DLL3 has been associated with tumor progression, poor prognosis and dedifferentiation in several NENs. This narrative review examines the current evidence about DLL3, its structure, function and association with tumorigenesis in NENs. Ongoing studies exploring the role of DLL3 as an emerging diagnostic marker are reviewed. Promising therapeutic options, such as antibody-conjugated drugs, CAR-T cells and radioimmunoconjugates, are also discussed.

Abstract Image

查看原文本刊更多论文

DLL3 作为神经内分泌肿瘤的潜在诊断和治疗靶点：叙述性综述。

神经内分泌肿瘤（NENs）因其异质性和有限的治疗方案而成为诊断和治疗的难题。传统的成像技术和治疗策略在随访过程中可能会变得不可靠，因为这些肿瘤随着时间的推移容易发生再分化。因此，需要新的诊断和治疗方案来治疗 NEN 患者。δ样配体3（DLL3）是Notch受体的一种抑制性配体，它已成为NENs新型诊断和治疗策略的潜在靶点，因为在几种NENs中，DLL3的过度表达与肿瘤进展、预后不良和去分化有关。这篇叙述性综述探讨了有关 DLL3、其结构、功能以及与念珠菌病肿瘤发生相关性的现有证据。本文还回顾了正在进行的探索 DLL3 作为新兴诊断标志物的研究。还讨论了前景看好的治疗方案，如抗体结合药物、CAR-T 细胞和放射免疫结合剂。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Critical reviews in oncology/hematology 医学-血液学

CiteScore

11.00

自引率

3.20%

发文量

213

审稿时长

55 days

期刊介绍： Critical Reviews in Oncology/Hematology publishes scholarly, critical reviews in all fields of oncology and hematology written by experts from around the world. Critical Reviews in Oncology/Hematology is the Official Journal of the European School of Oncology (ESO) and the International Society of Liquid Biopsy.